Latest Amides Stories
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
- Phase I study results presented at American Society of Hematology Annual Meeting RIDGEFIELD, Conn., Dec. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
RnRMarketResearch.com adds “Market Research Report on Global and Chinese Olaparib (CAS 763113-22-0) Industry, 2009-2019” Latest Report to its store. Dallas,
The Xarelto Lawsuit Complaint Alleges That Janssen Pharmaceuticals And Bayer HealthCare Did Not Disclose The Bleeding Risks Associated With The Prescription Blood Thinner Medication.
Erectile Dysfunction Data Presented in Two Moderated Posters; Findings Enable a Better Understanding of the STENDRA Clinical Profile and Provide Additional Data Regarding the Use of STENDRA as Early
- Retrospective analysis of more than 38,000 patients shows PRADAXA is associated with lower rates of stroke and major bleeding compared to warfarin RIDGEFIELD, Conn., Nov.
- Effects of idarucizumab on an exploratory marker of blood clotting, presented at the American Heart Association's Scientific Sessions RIDGEFIELD, Conn., Nov.
Findings presented at American Heart Association's Scientific Sessions add to growing body of data supporting safety and effectiveness of PRADAXA RIDGEFIELD, Conn., Nov.
CHAPEL HILL, N.C., Nov. 14, 2014 /PRNewswire/ -- In 1997, Novartis launched its antihypertension treatment Diovan into a crowded marketplace.
- The governor of a province or people.